Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.87M Buy
101,980
+70,300
+222% +$4.68M 0.13% 59
2026
Q1
$1.99M Hold
31,680
0.05% 66
2025
Q4
$2.1M Hold
31,680
0.04% 76
2025
Q3
$2.13M Hold
31,680
0.05% 77
2025
Q2
$2.77M Hold
31,680
0.08% 71
2025
Q1
$2.16M Hold
31,680
0.08% 79
2024
Q4
$2.46M Hold
31,680
0.08% 73
2024
Q3
$2.12M Buy
31,680
+25,800
+439% +$2.12M 0.07% 74
2024
Q2
$667K Hold
5,880
0.02% 86
2024
Q1
$816K Hold
5,880
0.03% 90
2023
Q4
$730K Hold
5,880
0.03% 80
2023
Q3
$549K Hold
5,880
0.03% 84
2023
Q2
$756K Hold
5,880
0.04% 91
2023
Q1
$683K Buy
+5,880
New +$658K 0.03% 86

Other funds holding DXCM

Aaron Cowen's DXCM Position: Q2 2026 in Review

Aaron Cowen increased its DexCom (DXCM) stake by 222% in Q2 2026, buying an estimated $4.68M and bringing the position to 101,980 shares worth $6.87M. The position accounts for 0.13% of the portfolio, ranked #59.

Aaron Cowen first reported a position in DXCM in Q1 2023 and has held it in 14 quarters since. 966 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Aaron Cowen held 101,980 shares of DexCom worth $6.87M as of Q2 2026.
  • Aaron Cowen bought 70,300 DexCom shares in Q2 2026, an estimated $4.68M.
  • DexCom made up 0.13% of Aaron Cowen's portfolio in Q2 2026, its #59 holding.
  • Aaron Cowen first reported a position in DexCom in Q1 2023 and has held it in 14 quarters since.
  • 966 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.